The pressure is on for those earnings to support the market's current valuations, after weeks of choppy trading.» Read More
What’s the biggest event of the year for biotech and big pharma? It’s the 43rd ASCO Annual Meeting where drug companies present new research that could indicate whether their cancer drugs are blockbusters or duds. It starts this Friday night in Chicago - what should you expect?
Severe kidney failure and some deaths have been reported in patients using Novartis's iron overload drug Exjade, the Food and Drug Administration said.
The market may see a Democratic congress (and possibly the White House in 2008) as detrimental to health care stocks -- but Henssler Financial Group's Ted Parrish begs to disagree. Parrish, the co-portfolio manager of the firm's Henssler Equity Fund joined "Squawk on the Street" to tout the opportunities in health care companies -- and name his favorites.
Michael Krensavage, pharmaceutical analyst at Raymond James, told CNBC’s “Morning Call” that strong revenue and earnings growth will reward investors in the pharmaceutical sector.
A new study offers the millions of people who have osteoporosis the hope of taking a drug to treat it only once a year. The New England Journal of Medicine reports that patients who got a once-a-year infusion of the Novartis drug Reclast saw a 70% reduction in the risk of spinal fractures and a 40% drop in the risk of hip fractures.
Several other major drug companies were apparently interested in buying MedImmune, including Merck, Eli Lilly and possibly Novartis, CNBC’s David Faber reported Tuesday.
Stocks closed lower as cautious comments from GM and Pfizer snapped the Dow's seven-day winning streak. "We've seen a really good move in the market and a little consolidation is healthy," said Bill Nichols, managing director of equity trading for Bear Stearns. "After being higher so much, a little profit-taking is only natural."
Strong sales of its flagship drugs boosted net profit at Swiss drugmaker Novartis by 11% to $2.171 billion, the group said on Monday, confounding expectations for a weaker profit.
Health care and insurance are two of the fastest-growing segments of the booming pet market. And big drug makers such as Pfizer, Novartis and Eli Lilly have taken note.
The maker of the FluMist vaccine said it was putting istself up for sale, causing its shares to surge more than 10%. MedImmune also said that certain major drugmakers had already indicated they might be interested in a takeover.
Stocks closed with broad gains as investors bought up large cap stocks, shrugging off a 3% gain in oil prices. "People are looking for a little bit of value, particularly in the large cap sector," said Dan McMahon, head of listed trading at CIBC World Markets. "It's not a huge move but we stopped the bleeding today."
Here are today's trivia questions for the Bonus Bucks. They're certainly worth the "effort" and add to your portfolio. The video question is worth $2,000 bonus bucks: Which of the following is NOT a feature of a $350 million complex being built in Dubai? Answers: Office space OR 360-degree rotating floors OR Hotel rooms OR 78 stories?
U.S. biotechnology company MedImmune has hired Goldman Sachs to explore a sale of the company, which has a market capitalization of $8.8 billion, people familiar with the situation said on Thursday.
Nestle, the world's largest food company, will buy U.S. baby-food giant Gerber from NovartisAG for $5.5 billion in cash, becoming the world's biggest baby food company.
Nestle is expected to announce a $5 billion deal to acquire baby-food maker Gerber from Swiss drugmaker Novartis , sources familiar with the situation told Reuters on Wednesday. An announcement is expected on Thursday, sources said.
An experimental bowel drug from GlaxoSmithKline and its partner Adolor has little commercial future following safety problems that caused trials to be put on hold, analysts said on Tuesday.
Novartis pulled bowel drug Zelnorm from U.S. shelves on Friday at the request of regulators because clinical trial data indicated a possible link to heart attacks and strokes.
Novartis cut its 2007 sales forecast on Friday after pulling bowel drug Zelnorm from U.S. shelves at the request of regulators because clinical trial data indicated a possible link to heart attacks and strokes.
The Fast Money Five give their picks for the hottest trades. Tonight, the burning rubber rally, the call ahead of Costco earnings and more...
Novartis AG's high blood pressure pill, Tekturna, won U.S. regulatory approval, calming investor fears about the firm's ability to get new drugs to market and boosting its shares nearly 4%.